Barclays raises Amgen price target to $400, keeps Equal-Weight

Barclays raised Amgen's price target from $380 to $400. Analyst Emily Field maintained an Equal-Weight rating. The price target increase amounts to $20 per share.

Amgen turns $100 into $747 with 14.3% annualized return over 15 years

$100 invested 15 years ago is now worth $747.45. Average annual return stands at 14.3%. Outperformed the market by 1.45% annually. Current market capitalization is $230.37 billion.

Ohio Rep. David Taylor buys up to $45K worth of Amgen stock

Rep. David Taylor bought Amgen stock valued between $3,003 and $45,000 on September 22, 2026. The purchase was disclosed in an October 1, 2026 filing under the STOCK Act requirements. Taylor has made 231 trades totaling over $357 thousand in the past three years. Recent activity also included sales of Microsoft and Marathon Petroleum shares.

Amgen hits primary endpoint in Sjögren's Phase 3 trial

Amgen's dazodalibep met the primary endpoint in the Phase 3 OASIZ 301 trial for Sjögren's disease. Patients showed statistically significant improvement in ESSDAI scores at 48 weeks, with effects visible from Week 4. Safety profile showed low discontinuation rates and no increased risk of thromboembolic events versus placebo. Approval filing awaits the OASIZ 303 trial readout, projected for Q4 2026, per analyst expectations.

Amgen stock falls 9.8% as Novartis trial failure weighs on sentiment

Amgen stock fell 9.8% to $394.56, its worst daily loss since October 2000. Novartis pelacarsen failed Phase 3 cardiovascular endpoints despite lowering Lp(a). Amgen's olpasiran faces scrutiny as it targets the same lipid via different mechanism. BMO Capital downgraded Amgen to Market Perform amid broader biotech sell-off. iShares Biotechnology ETF (IBB) dropped 1.8% following the news.

Amgen Repatha cuts death risk by 20% in high-risk primary prevention trial

Amgen's Repatha reduced death risk by 20% in high-risk adults without prior heart attack or stroke. Findings from Phase 3 VESALIUS-CV trial presented at ESC Congress 2026 in Munich. Study included over 12,000 patients; benefits persisted through 4.6-year median follow-up. Drug also showed 36% reduction in heart attack risk and lowered LDL-C significantly.